14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
HOLX vs XRAY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over DENTSPLY SIRONA Inc. (XRAY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas XRAY carries 42.5/100 (HOLD) at $8.29 (6.8x Forward P/E, 4.7% operating margin).
Technical & Structure Timing Caution: HOLX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 69.0); meanwhile XRAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HOLX vs XRAY. Trailing 12-month operating profitability (HOLX 23.0% vs XRAY 4.7%) and valuation multiples (HOLX 20.1x vs XRAY 6.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $1.7B market capitalization and 4.7% operating margin.
OpEx & R&D Reinvestment45.8% of Rev ($1.64B)
90D Engineering Disclosures0 Published
Investor FAQ HOLX vs XRAY Key Questions & Quantitative Answers
As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over DENTSPLY SIRONA Inc. (XRAY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas XRAY carries 42.5/100 (HOLD) at $8.29 (6.8x Forward P/E, 4.7% operating margin). Technical & Structure Timing Caution: HOLX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 69.0); meanwhile XRAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
HOLX leads the Growth & Scale pillar: HOLX posts +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin), compared with XRAY at -7.5% YoY revenue growth and +15.2% YoY earnings growth on $3.58B TTM revenue (50.5% gross margin, 4.7% operating margin). On trailing 12-month operating scale, HOLX generates $4.13B in USD-normalized revenue versus $3.58B for XRAY. In operating R&D and SG&A reinvestment, HOLX deploys 37.4% of Rev ($1.54B) (0 90-day corporate R&D disclosures) versus 45.8% of Rev ($1.64B) (0 disclosures) for XRAY.
XRAY screens cheaper on headline valuation multiples. HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin), whereas XRAY trades at 6.8x Forward P/E, 6.6x Trailing P/E, 0.66x PEG, and 1.1x EV/Revenue (2.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HOLX (10.9% ROE) versus XRAY (-8.6% ROE) capital efficiency.
In options market volatility and institutional positioning, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk). By comparison, XRAY carries 26.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.86β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.